Research programme: autologous diabetes cell therapy - Orgenesis

Drug Profile

Research programme: autologous diabetes cell therapy - Orgenesis

Alternative Names: AIP cells - Orgenesis; Autologous insulin producing cells - Orgenesis

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Tel Hashomer Medical Research Infrastructure and Services
  • Developer Orgenesis
  • Class Cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus; Type 1 diabetes mellitus

Most Recent Events

  • 28 Feb 2017 Orgenesis has patent protection for autologous diabetes cell therapy in USA and countries outside the USA (Orgenesis 10-K, February 2017)
  • 28 Feb 2017 Orgenesis has patents pending for autologous diabetes cell therapy in USA, Europe, Australia, Brazil, Canada, China, Eurasia, Israel, Japan, South Korea, Mexico, and Singapore (Orgenesis 10-K, February 2017)
  • 17 Dec 2015 Orgenesis plans a phase I/II trial for Type-1 diabetes mellitus in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top